Problem Solution: Gene One
Wall Street was showing a growing interest in the biotech industry. Gene One had entered the industry just eight years earlier and had succeeded from a $2 million entrepreneurial start-up to a $400 million operation. With favorable changes in leadership of the Food and Drug Administration and investor confidence in the industry, Gene One's CEO Don Ruiz and the Board of Directors saw an opportunity to becoming the leader in biotechnology and saw growth potential at an annual rate of 40%.
To achieve the growth pace set forth by the board it was felt that Gene One should enter the public market within the next three years. This will not be an easy undertaking. While the senior leadership team has brought Gene One to success as a corporation, the team does not have the skills or knowledge necessary for filing the IPO. The good news is that the senior leadership team knows how to be successful and they will require bringing in professionals to help with the filing.
What this paper offers is a look at all sides of the issues and a better understanding of the stakeholders and their respective positions on the future direction of Gene One.
Situation Analysis
Issue and Opportunity Identification
Gene One has gone from an entrepreneurial concept to over a $400 million dollar company today. This was done in the time span of eight years. With breakthrough gene technology it has given Gene One and the researches name recognition. To capitalize on the success Gene One has enjoyed and to continue to have potential growth in the marketplace, the Board of Directors have charged the senior leadership team with presenting an IPO offering within 36 months.
Stakeholder ...